These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 16719539)

  • 21. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects and side effects of transdermal scopolamine for premedication in general anesthesia in elderly patients].
    Tolksdorf W; Baumann S; Heine C; Hettenbach A
    Anasth Intensivther Notfallmed; 1986 Dec; 21(6):301-6. PubMed ID: 3544938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.
    Pyykkö I; Schalén L; Jäntti V
    Acta Otolaryngol; 1985; 99(5-6):588-96. PubMed ID: 4024909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study on effect of acupoint sticker of TTS-ST93-1 in treating motion sickness].
    Pei J; Yang T; Liu Z
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Aug; 18(8):464-7. PubMed ID: 11477828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Transdermal scopolamine (TTS-scopolamine) for the prevention of postoperative nausea and vomiting].
    Tolksdorf W; Meisel R; Müller P; Bender HJ
    Anaesthesist; 1985 Dec; 34(12):656-62. PubMed ID: 4096357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of salivary flow with Scopoderm TTS.
    Talmi YP; Finkelstein Y; Zohar Y; Laurian N
    Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):128-30. PubMed ID: 3355042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose escalation pharmacokinetics of intranasal scopolamine gel formulation.
    Wu L; Boyd JL; Daniels V; Wang Z; Chow DS; Putcha L
    J Clin Pharmacol; 2015 Feb; 55(2):195-203. PubMed ID: 25187210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delirium due to scopolamine patch in a 4-year-old boy.
    Lin YG; Chen PH; Chang FY; Wu LT; Liao KY; Wu TC
    J Formos Med Assoc; 2011 Mar; 110(3):208-11. PubMed ID: 21497284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal scopolamine in motion sickness.
    Cronin CM; Sallan SE; Wolfe L
    Pharmacotherapy; 1982; 2(1):29-31. PubMed ID: 6927209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine.
    Weerts AP; Pattyn N; Putcha L; Hoag SW; Van Ombergen A; Hallgren E; Van de Heyning PH; Wuyts FL
    J Psychopharmacol; 2015 Dec; 29(12):1231-5. PubMed ID: 26268532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.
    Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D
    Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique Scopolamine Withdrawal Syndrome After Standard Transdermal Use.
    Manno M; Di Renzo G; Bianco P; Sbordone C; De Matteis F
    Clin Neuropharmacol; 2015; 38(5):204-5. PubMed ID: 26366965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness.
    Al-Ghananeem AM; Malkawi AH; Crooks PA
    Drug Dev Ind Pharm; 2007 May; 33(5):577-82. PubMed ID: 17520450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.